person · Reporting owner

RAAB MICHAEL

Disclosed activity across 3 companies

Tapewire entity: 19876
SEC CIK: 0001321402

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARDELYX, INC.ARDX · Entity 4972	Director · President & CEO	August 21, 2026	August 25, 2026
Tempest Therapeutics, Inc.TPST · Entity 7734	Director	January 27, 2026	January 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARDELYX, INC.

Report date August 21, 2026 · Filed August 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,619,792	Ending reported balance After 2026-08-21 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-08-21 · Sale · Disposed 15,009 · Balance 1,663,357 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 2 · 2026-08-21 · Sale · Disposed 15,976 · Balance 1,647,381 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-21 · Sale · Disposed 8,411 · Balance 1,638,970 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 4 · 2026-08-21 · Sale · Disposed 19,178 · Balance 1,619,792 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	24,364	Reported balance Holding disclosure · report date 2026-08-21 · row 5 Holding and transaction disclosures are not merged. 1 source row Row 5 · Balance 24,364 F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.
Common StockSEC Table I · non-derivative	IndirectFamily Trust	1,000	Reported balance Holding disclosure · report date 2026-08-21 · row 6 Holding and transaction disclosures are not merged. 1 source row Row 6 · Balance 1,000 F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. The transaction was executed in multiple trades in prices ranging from $3.648 to $3.984, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F2: The shares are directly held by Michael G. Raab, Trustee of the Michael G. Raab Living Trust dated July 25, 2012.

F3: The shares are owned directly by trusts for the benefit of the Reporting Person's children.

Tempest Therapeutics, Inc.

Report date January 27, 2026 · Filed January 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2036-01-26	Direct	1,230	Reported balance After 2026-01-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-27 · Grant · Acquired 1,230 · Balance 1,230 F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMICUS THERAPEUTICS, INC.

Report date April 27, 2026 · Filed April 27, 2026

Section 16 reporting ended · disclosed 2026-04-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-04-27 transaction · row 1 1 source row Row 1 · 2026-04-27 · Disposition to issuer · Disposed 115,857 · Balance 0 F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.71 · Expires 2026-06-09	Direct	Reported balance After 2026-04-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-27 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.60 · Expires 2027-06-13	Direct	Reported balance After 2026-04-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-27 · Disposition to issuer · Disposed 16,236 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.00 · Expires 2029-06-27	Direct	Reported balance After 2026-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-04-27 · Disposition to issuer · Disposed 19,473 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.81 · Expires 2030-06-04	Direct	Reported balance After 2026-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-04-27 · Disposition to issuer · Disposed 18,574 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.71 · Expires 2031-06-10	Direct	Reported balance After 2026-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-04-27 · Disposition to issuer · Disposed 36,111 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.55 · Expires 2032-06-09	Direct	Reported balance After 2026-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-04-27 · Disposition to issuer · Disposed 45,423 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.62 · Expires 2033-06-08	Direct	Reported balance After 2026-04-27 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-04-27 · Disposition to issuer · Disposed 30,474 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.27 · Expires 2034-06-06	Direct	Reported balance After 2026-04-27 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-04-27 · Disposition to issuer · Disposed 42,467 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F3: Each Option was fully vested.
Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.96 · Expires 2035-06-05	Direct	Reported balance After 2026-04-27 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-04-27 · Disposition to issuer · Disposed 74,872 · Balance 0 F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. F4: Each Option vested in full in connection with consummation of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 95,443 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).

F2: In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.

F3: Each Option was fully vested.

F4: Each Option vested in full in connection with consummation of the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 12, 2017 Filed Oct 17, 2017 01:10 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $7.15	$0.00	Disclosure SEC source: 0001209191-17-057054 · doc4.xml · derivative · entry 4 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2019-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document
October 12, 2017 Filed Oct 17, 2017 01:10 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionStock Options (right to buy) · Derivative	5,000	$0.00 Strike: $10.53	$0.00	Disclosure SEC source: 0001209191-17-057054 · doc4.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2018-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. Read SEC document
October 12, 2017 Filed Oct 17, 2017 01:10 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	SaleCommon Stock	10,000	$14.25	$142,534.00	Disclosure SEC source: 0001209191-17-057054 · doc4.xml · nonDerivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. F3 · price: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document
October 12, 2017 Filed Oct 17, 2017 01:10 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	Exercise / conversionCommon Stock	10,000	$14.25	$142,534.00	Disclosure SEC source: 0001209191-17-057054 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. F2 · price: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.43. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document
August 09, 2017 Filed Aug 11, 2017 21:08 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	79,535	$0.00 Strike: $4.70	$0.00	Disclosure SEC source: 0001140361-17-031447 · doc1.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,535 Underlying: Common Stock · 79,535 shares Expires 2027-08-09 F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest with respect to 2/3 of the shares subject thereto on December 31, 2018 and 1/3 of the shares subject thereto on June 1, 2019, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
August 07, 2017 Filed Aug 11, 2017 21:08 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	79,535	$0.00	$0.00	Disclosure SEC source: 0001140361-17-031447 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document
June 13, 2017 Filed Jun 15, 2017 20:20 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantStock Options (right to buy) · Derivative	16,236	$0.00 Strike: $8.60	$0.00	Disclosure SEC source: 0001209191-17-040128 · doc4.xml · derivative · entry 2 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,236 Underlying: Common Stock · 16,236 shares Expires 2027-06-13 F1 · derivative.exercise_date: One hundred percent of the shares subject to this option will vest and become exercisable on the date of the annual meeting of the stockholders of the issuer to be held in 2018. Read SEC document
June 13, 2017 Filed Jun 15, 2017 20:20 UTC	AMICUS THERAPEUTICS, INC. FOLD · Entity 51196	GrantCommon Stock	5,814	$0.00	$0.00	Disclosure SEC source: 0001209191-17-040128 · doc4.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,814 Read SEC document
January 19, 2017 Filed Jan 24, 2017 01:53 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantStock Option (Right to Buy) · Derivative	318,141	$0.00 Strike: $13.90	$0.00	Disclosure SEC source: 0001140361-17-002606 · doc1.xml · derivative · entry 3 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,141 Underlying: Common Stock · 318,141 shares Expires 2027-01-19 F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 19, 2017, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document
January 19, 2017 Filed Jan 24, 2017 01:53 UTC	ARDELYX, INC. ARDX · Entity 4972	GrantCommon Stock	17,985	$0.00	$0.00	Disclosure SEC source: 0001140361-17-002606 · doc1.xml · nonDerivative · entry 1 RAAB MICHAEL · CIK 0001321402 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,503 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.